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Abstract
Cardiovascular diseases constitute one of the main aetiologies of mortality among patients with cancer. Population ageing and
cancer survival rate improvements have resulted in the coexistence of cardiovascular diseases and malignancies in an increas-
ing number of patients. With the diversity in treatments and the introduction of new drug lines, multiple mechanisms of car-
diovascular injury have been recognized in these patients.
Cardio-oncology is an emerging entity introduced to provide a proper solution to the several challenges encountered in the
management of patients with cancer and cardiac involvement.
This review will assess the logical grounds for establishing a cardio-oncology unit, describe the main objectives and the detailed
responsibilities in such systems, and outline the target population. Furthermore, the importance of research and appropriate
data collection will be highlighted. Lastly, the special considerations and modifications required for setting up such centres in
the developing countries are discussed.
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Introduction
Cardio-oncology: a noteworthy emerging
discipline
Cancer and cardiovascular diseases (CVDs) are the two most
common non-communicable diseases that cause the highest
global mortality.1 In recent years, the growing volume of el-
derly populations and the improvement in overall survival
rates have led to the coexistence of CVDs and malignancies
in a large group of patients.
Similarities have been observed among the patterns of the
geographic distributions of the mortality of patients with
CVDs and cancer, which are believed to be a result of com-
mon risk factors in the pathogenesis of diseases such as
smoking, hyperlipidaemia, and obesity.2 Additionally, there
is an increased risk of CVDs and its risk factors among
candidates for oncological treatments.3 On the other hand,
the overall improvement in the treatment outcomes of pa-
tients with cancer has led to an increased incidence of the
cardiovascular side effects of the mentioned treatments.
Moreover, cardiovascular events have been recognized as a
major cause of mortality among cancer survivors, which in
some cancer types might exceed the mortality rate related
to the reoccurrence of the baseline malignancy.4,5
With the increased survival of patients and the diversity in
treatments, multiple mechanisms of injury have been recog-
nized that can affect the entire cardiovascular system. Al-
though there are no official guidelines, there exist
recommendations regarding the monitoring and manage-
ment of complications in different categories.6,7
Addressing the challenges associated with the care of
these patients has ushered in a new branch of medicine
called ‘cardio-oncology’. The main purpose of this specialty
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is to consider both aspects of cardiology and oncology in a pa-
tient, creating a bridge between the two fields in order to
make the best decisions regarding the prevention, monitor-
ing, and treatment of the diseases. An overview of the gen-
eral design of a cardio-oncology unit (COU) is depicted in
Figure 1.
In this review article, we aim to describe the rationale for
establishing a COU. Furthermore, we will explain the general
objectives and the detailed responsibilities in such systems,
identify the target population, and define the importance of
research in this context. Lastly, we will discuss the special
considerations and modifications required for establishing
such centres in developing countries.
Purpose
Cardio-oncology services are designed to provide extensive
cardiovascular care to patients with cancer. This comprehen-
sive care includes actions before, during, and after the com-
pletion of the cancer treatment (Figure 2).
A complete evaluation of the patient’s baseline cardiovas-
cular state, risk factors, and previous history should be per-
formed prior to the initiation of any treatment.
Subsequently, risk stratification is done based on the men-
tioned assessments. Primary prevention measures should be
implemented as needed, and the treatment of any underlying
cardiovascular conditions should be optimized. The cardiovas-
cular risk of each treatment strategy should be discussed
carefully within the cardio-oncology team and weighed
against its effectiveness in cancer treatment. Finally, when
the proper treatment is selected, the means and frequency
of monitoring the cardiovascular function during the treat-
ment process should be planned. Importantly, lack of specific
cardio-oncology discipline might result in the misclassification
of patients into higher cardiovascular risk categories and,
consequently, their deprivation of a vital chemotherapy
programme.
During the course of treatment, ongoing and arranged
monitoring should be implemented. When cardiovascular
side effects are encountered, the challenging decision will
be to determine whether to continue or discontinue the
treatment. The goal is to interrupt the cancer treatment as
briefly as possible while minimizing the detrimental effects
on the cardiovascular system. Of note, one study linked the
interruptions in trastuzumab courses with a higher rate of
cancer recurrence among patients suffering from breast
cancer.6,8,9
Long-term side effects of cancer treatments can develop
years later. Therefore, the selection of the proper strategy
for long-term follow-ups after the completion of treatment
and the adherence of patients to the programme are
important.
Although the main focus of cardio-oncology has been the
monitoring and treatment of the cardiovascular toxicity of
cancer therapies, several other issues need to be addressed
in this regard.
Evidence shows that cardiac surgeries have an increased
rate of complications and mortality among patients suffering
Figure 1 Overview of the design and function of a cardio-oncology unit. After first-level evaluations, patients in need of further workup are referred to
the cardio-oncology unit, where risk stratification based on imaging and laboratory data is performed and individualized treatments and monitoring
programs of each patient are planned. CMR, cardiac magnetic resonance imaging; LAB, laboratory.
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from cancer with a history of radiation. This includes both pa-
tients with radiation-induced valvular disease that require
surgery (increased operative mortality of 3.8% vs. 0.8% and
a 2.2-fold higher risk of decreased long-term survival)10 and
patients with a history of radiation that need cardiac surgery
due to other aetiologies such as coronary artery bypass graft
surgery (72% survival rate after 7.6 ± 3 years follow-up in the
control group vs. 45% survival in the radiation group).11 Con-
sidering the mentioned complications in surgical procedures,
interventional strategies such as transcatheter aortic valve
implantation and percutaneous coronary intervention are
performed increasingly among these patients.12 Indubitably,
the application of interventional strategies in this high-risk
population needs meticulous risk stratification.
A significantly increased rate of acute coronary syndromes
(up to threefold) has been reported among patients with can-
cer, especially those with active malignancy.13 The
hypercoagulative state, increased bleeding risks, and the
probable need for withholding antiplatelet agents are some
of the main challenges encountered in choosing the optimal
management strategy.14,15
Logistics and requirements
Team members and staff
A number of specialists and healthcare providers are prereq-
uisites for a successful COU. A cardio-oncologist, a cardiolo-
gist with some expertise in heart failure or cardiac imaging,
is often considered to be the leader of the team.16,17 Medical
oncologists, radiation oncologists, and haematologists are the
other members that comprise the core of the team, along
with nurses that specialize in the field. Other healthcare pro-
fessionals including surgeons, pathologists, palliative care
specialists, nutritionists, and psychologists may assist the
team on a case-based basis (Figure 3).6,7 Furthermore, pri-
mary care physicians are regarded as the supportive mem-
bers of cardio-oncology teams on the strength of their
contribution to the risk-factor modification and long-term
surveillance of patients.
Location
The COU can be set up in an oncology centre or a
cardiology-based establishment. A clear consensus has yet
to emerge on what constitutes the most appropriate ap-
proach, and there are several pros and cons to each of the
choices.
A clinic set-up in an oncology-based hospital confers better
accessibility to patients. The rate of loss to follow-up can also
be diminished by allowing patients to receive both cardiology
and oncology visits at the same location and preferably in the
same session. Furthermore, this approach can facilitate the
communication between the cardiologist and the oncologist
and provide more desirable contributions to tumour boards
and oncology grand rounds. On the other hand, accessibility
to cardiovascular imaging modalities may be limited within
the oncology-based clinic, and the staff will also be less famil-
iar with the routine measures of cardiovascular care or infor-
mation to provide to patients, which favours the
cardiology-based setting.
Figure 2 Objectives of the COU during the stages of cancer management. Detailed objectives of a COU, before, during, and after cancer treatment are
illustrated. COU, cardio-oncology unit.
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Workflow
As awareness regarding the need for the COU is raised, insti-
tutional structures, protocols, and resources can be arranged.
Promoting and publicizing the cardio-oncology centre and
its mission are of great significance. Presentations, work-
shops, letters, and face-to-face conversations should be used
in order to increase awareness regarding the importance of
this relatively novel entity and the need for its development
among various levels of healthcare professionals.18
The clinical model of the unit should be designed thor-
oughly. There is a wide spectrum of cardiovascular adverse
effects due to cancer treatment. Considering the limitations
in resources and services, especially in the initial stages of es-
tablishing these centres, it is vital to define and limit the exact
services that will be covered by the unit before initiating the
process. Detailed descriptions of which patients are to be re-
ferred to the clinic must be defined. The volume of the work
should be predicted and planned to be fully manageable by
the available resources. For instance, a COU in a referral cen-
tre for patients with breast cancer should be experienced
about cardiotoxicity management and equipped with se-
lected imaging modalities recommended for a precise evalua-
tion of the left ventricular systolic function. Nonetheless, in a
centre with the target population of gastrointestinal malig-
nancies, the focus of evaluations should be on monitoring
blood pressure and QT prolongation, which are the main side
effects of vascular endothelial growth factor receptor
inhibitors.19
Another issue that should be considered is the ease of
communication between the cardiology and the oncology
teams and their access to patients’ medical records. Changes
in treatment or imaging results and lab data should be well
documented and readily accessible to all team members. In
this regard, electronic documentation is the preferred
method as it simplifies data sharing among different depart-
ments; still, in the case of unavailability, classic methods can
also be implemented.20
It has been demonstrated that increased waiting times for
chemotherapy can result in decreased survival among pa-
tients with cancer.21–23 The optimal goal of the team is to de-
liver the required services on a same-day basis. This may not
be feasible depending on the availability of resources in some
units, but solutions and practical approaches to reach this
goal should be sought. In the event of persistent shortages
of resources, patients can be prioritized at the discretion of
the team’s oncologist. Electronic consultations have been ar-
ranged in some centres to facilitate and expedite the process
and to reduce the need for the transportation of patients be-
tween centres. However, some studies have shown that pa-
tients favour face-to-face consultations.19
The multidisciplinary approach of the team should be im-
plemented as was discussed earlier. The cardiologist in charge
of patients should be in close and continuous communication
Figure 3 Cardio-oncology team members. Team members consist of two groups: core members including the team leader, who should be invariably
engaged in each patient’s management process; and contributory members from various specialties, who are consulted on a case-based basis and as
needed.
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with the oncologists, and they should plan the treatment pro-
gramme together considering the cardiovascular and onco-
logical aspects of the disease. Any changes during the
planning of the treatment or after the initiation of the treat-
ment course should be addressed in the same manner.
Finally, patients’ contribution and adherence to the pro-
gramme are crucial. It is the responsibility of the team mem-
bers, not least the professional nurses, to inform patients
about the importance of continuous cardiovascular monitor-
ing while undergoing cancer treatment. The common cardio-
vascular symptoms of treatments should be explained to
patients and their caregivers so that they are alert in case side
effects occur. Furthermore, accurate schedules and frequent
reminders should be provided by the medical staff to pa-
tients, especially in the post-treatment stage when late car-
diovascular side effects may develop.
Education and training
With the increasing rate of cancer survivors and their com-
mon comorbidities, a more significant shortage of staff and
professionals in the field is predicted in the near future,
which highlights the need for the training of expert
healthcare providers in this regard.
A comprehensive understanding of diagnostic and thera-
peutic methods in oncology and cardiovascular medicine will
result in the optimal management of patients suffering from
cancer with a concomitant focus on the cardiac and oncolog-
ical aspects of the disease, which could eventually lead to
better outcomes. The aim of cardio-oncology fellowship train-
ing programs is to achieve such insights.24
Research has shown that cardio-oncology lectures were in-
cluded in only 10% of cardiology training curricula, and 40%
of cardiology programs did not have any official training
course for oncology-related topics.25
Training programs for cardio-oncology are defined at three
levels by the International Cardio-Oncology Society and the Ca-
nadian Cardiac Oncology Network.24 Level 3 is considered a fel-
lowship and consists of at least a 1-year training programme in
this field. The trainee is usually a cardiologist but could also be
an oncologist.24,25 Level 2 education is mostly for primary care
providers and includes the awareness of potential CVDs and in-
sights regarding the optimal time to refer a patient to a specialist.
Level 1 education encompasses a basic understanding of issues
concerning the cardio-oncology subject.
Strong fellowship programs require high-volume centres
with in-patient and out-patient clinics. Faculty members with
expertise in advanced imaging modalities such as echocardi-
ography, magnetic resonance imaging, and nuclear medicine
are essential. Ideally, heart failure specialists, electrophysiolo-
gists, interventionalists, and also cardiac surgeons should be
accessible for consultations.25
Research
Research is the cornerstone of a COU. As cardio-oncology is a
newly recognized concept, the evidence regarding this field is
limited. There are no official guidelines in the cardiovascular
management of oncology patients, with only a few recom-
mendations having been made in this regard.6,7,9 Establishing
an organized COU can expand our understanding of the re-
lated issues, help develop new evidence, and gather reliable
data.
Each patient in the COU has different categories of medical
data (demographics, imaging, and pharmacology). Therefore,
strong multilayered databases are needed. Designing clinical
registries leads to accurate and goal-oriented data collection
and is a necessity for improvement in research quality.
Conducting clinical trials and participating in multicentre
studies result in an increased knowledge in the field.
Implementing the mentioned activities will eventually lead
to practical guidelines and recommendations in this field.
Cost effectiveness
Although there is increasing enthusiasm regarding the multidisci-
plinary management of patients, evidence on the true value of
this approach and its cost effectiveness is still lacking. There
has yet to be a study evaluating the cost effectiveness in the spe-
cific cardio-oncology multidisciplinary setting. Nonetheless, stud-
ies on the multidisciplinary management of patients with cancer
have had variable results.26 Previous research has shown that
the multidisciplinary management of patients with cancer has
conferred a more optimal staging assessment and improved ad-
herence to the guidelines.27 A recent study showed improved
survival in patients with haematological and lung cancers that
were assessed in multidisciplinary meetings. However, such ben-
efits were not significant among patients with colorectal and
breast cancers.28
Hence, further evidence is required to answer the question
of whether or not these clinics are truly cost effective.
Limitations and challenges
Some of the most common challenges in the implementation
of COUs are summarized in Table 1.9
Current status of cancers in developing
countries
There is an undeniable link between the status of cancer
prevalence and the need for COUs. Different facilities are
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required based on different epidemiological statuses. It has
been postulated that developed countries have reached a
peak in the prevalence of cancers, which is expected to de-
crease in the upcoming years. However, currently, nearly
two thirds of all cancer mortalities occur in low-income and
middle-income countries.29 Furthermore, a significant in-
crease in the incidence and prevalence of malignancies is ex-
pected in the next few decades among developing countries.
A study on cancer statistics in Iran predicted that there would
be a twofold increase in cancer incidence among Iranians in
the year 2035, compared with the year 2012, resulting in
184 481 new cases.30
General patterns in the prevalence and incidence of can-
cers are not similar among different countries, and there is di-
versity in different regions within the same country. The
recognition of these patterns can be useful in terms of plan-
ning future programs and creating the required infrastructure
for policymakers and healthcare providers in the field of
cancer.
Based on a systematic analysis for the global burden of dis-
ease study by Fitzmaurice et al., the most incident cancer
among high-income countries was non-melanoma skin can-
cer, followed by prostate, colon and rectal, and lung cancers.
Based on the same study, lung and breast cancers were the
most incident cancers in middle-income countries, whereas
cervical cancer still had the highest incidence among malig-
nancies in low-income countries. The most incident cancers
among Iran’s population are reported to be breast, stomach,
and prostate cancers, while stomach and lung cancers and
leukaemia cause the highest mortality.31 The most prominent
increase in the country is expected to be among oesophageal,
stomach, and prostate cancers in the upcoming years.30
The regional clustering of the prevalence of different cancers
is another issue worth mentioning. Iran has witnessed an in-
crease in the prevalence of breast cancer in its central (Tehran
and Alborz) provinces as reported by a study conducted by
Ahmadi et al.32 The highest incidence of lung cancer is reported
in central and also southern provinces,33 while gastrointestinal
cancers (especially oesophageal and stomach cancers) are more
prevalent in the northern and north-western provinces of the
country.34
The burst of cardiovascular risk factors and also
malignancy-related predictors observed in developing coun-
tries is another issue of significance. A number of causes
contribute to this increase, the most prominent of which is
the so-called ‘westernization’. This phenomenon has many
aspects including adopting a more sedentary lifestyle, dietary
changes towards the use of more processed foods, higher in-
takes of meats and sweets, and behavioural changes. As an
example, behavioural changes among women in low-income
countries such as delayed childbearing, lower parity, and de-
creased rates of breastfeeding have caused trends towards
an increased prevalence rate of breast cancer.30
The same challenges exist for the current increase in envi-
ronmental and occupational exposures to carcinogens in the
developing world. Lack of effective industrial hygiene, ineffec-
tive regulations, and inadequate education are the measures
contributing to this increase.31
Apart from the important impact of environmental and oc-
cupational factors, the diversity of genetic background exerts
a significant influence on the variability of cancer incidence.35
Ongoing challenges
The main concern of the medical community involved in
cardio-oncology is providing optimal services in terms of the
early and effective identification and management of cardio-
vascular complications among patients with cancer. Devising
preventive strategies to reduce the incidence of the men-
tioned adverse events would be a priority in this regard.
There are considerable variations in diagnostic and thera-
peutic processes in developing countries by comparison with
the developed world. Studies have shown that more than
70% of breast cancer cases are diagnosed in the early stages
(these numbers are above 90% in Norway and Sweden) in
high-income countries. However, the percentages are signifi-
cantly lower among low-income countries, and between 30%
and 80% of patients are diagnosed in the advanced stages of
III and IV, resulting in a remarkably increased burden of the
disease.36 This advanced group of patients is at a potentially
higher risk of cardiac involvement due to both increased co-
morbidities and the need for more potent cancer therapies.
Different health policies and infrastructure are applied in
developing countries based on the available resources.
Cancer-screening programs represent an integral component
of these policies in that they can lead to the earlier detection
and survival improvement of patients. However, limited re-
sources and financial problems in this part of the world re-
quire individualized approaches. Breast cancer screening is
one of the most studied subjects in this regard. Research
shows that implementing cost-effective screening programs
such as down-staging with the purpose of raising awareness
among patients and first-level health professionals and aug-
menting referral systems in lieu of such costly methods as
mammography screening may be useful in the context of de-
veloping countries.36
Table 1 Challenges in implementing cardio-oncology unit
Lack of medical community awareness regarding purpose and
function of the unit
Lack of specific guidelines and standardized administrative
protocols
Lack of assigned infrastructure and financial support for the unit
Shortage of cardio-oncology units and Incompatible volume of
patients to the available unit’s capacity
Shortage of cardio-oncology experts
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The same strategy should be adopted in regard to
cardio-oncology programs. Monitoring and follow-up
methods should be modified based on the available infra-
structure in the region. By way of example, recommendations
concerning the monitoring of patients receiving
anthracyclines suggest frequent measurements of the left
ventricular global longitudinal strain. Still, this might not be
practical considering that the required equipment is usually
only available in tertiary centres in most developing coun-
tries. It is the art of the head of the cardio-oncology team
to properly modify such recommendations without
compromising the patient’s care. In the mentioned scenario,
the serial monitoring of cardiac biomarkers and Doppler eval-
uations of peak systolic mitral excursion are alternative prac-
tical and relatively inexpensive methods than can be primarily
performed to identify high-risk patients and refer them to
centres with the necessary tools for further evaluations.7
Significant strides have been taken in the therapeutic man-
agement of cancers and have improved the overall survival of
patients in recent years. However, there are still multiple im-
pediments to the treatment of patients with cancer in the de-
veloping world, influencing the related facilities such as
cardio-oncology. Although there is a rather developed medi-
cal referral system in some developing countries, there is still
room for improvement. Patients in need of multidisciplinary
care are usually referred to a number of different medical
centres for each of their consultations, sometimes even in dif-
ferent cities, which can be exhausting, especially for patients
with cancer. Therefore, gathering the mentioned specialties
in a COU not only can be convenient for the patients but also
might be more cost effective.
While more than 60% of patients receive treatment in less
than 3-month intervals after symptom onset in high-income
countries, treatment is started in fewer than 30% of patients
with breast cancer in a 3-month interval in low-income coun-
tries. This delay results from both an increased ‘patient inter-
val’, defined as the time from symptom onset to seeking
medical consultation, and ‘treatment interval’, which reflects
the time from diagnosis until treatment commencement.36
The increasing costs of the emerging drug classes intro-
duced to the market make them unavailable to a significant
portion of patients in developing countries. Using generic
drugs, increasing participation in global clinical trials, and
expanding the insurance coverage are some of the policies
that can be considered to overcome this problem.29 Fortu-
nately, apropos of cardiovascular therapeutic options for
treating cancer-related complications, the required medica-
tions are mostly inexpensive, covered by insurance, and read-
ily available. Consequently, an appropriate and organized
system with effective screening for the early detection of can-
cer patients with cardiac involvement can provide the re-
quired therapeutic services.
Radiotherapy and its related cardiovascular complications
are other topics of concern in cardio-oncology. Importantly,
the absence of widespread access to radiotherapy is an im-
portant issue in developing countries. It has been reported
that about 50% of patients with cancer will need radiother-
apy at least once during their illness. In low-to-medium-
income countries, a higher percentage of patients are in need
of radiotherapy compared with high-income countries.37 This
is in part due to the type of cancers. Additionally, as the tu-
mours are recognized at higher stages, they are less amena-
ble to surgery.
Zubizaretta et al. reported that 4221 teletherapy machines
were available in low-to-middle-income countries,
representing only 38% to 49% of the required devices based
on the used benchmark. Of note, 39 of the countries did
not provide any radiotherapy services. The same study sug-
gested that between 4320 and 6958 additional machines
were needed in these countries in order to meet patient
demands.37
Finally, the growing number of patients undergoing cancer
treatments warrants an expansion of cardiovascular monitor-
ing systems. There are inconclusive data regarding the magni-
tude of patients currently covered by cardio-oncology
programmes in developing countries. The equipment and ex-
pertise in each COU should be designated based on the spec-
ifications of the patients referred to the facility (e.g. the
prevalent malignancies and their related treatment strategies
in the region). Be that as it may, the majority of the few spe-
cialized facilities in this field are concentrated in large tertiary
hospitals in central cities, limiting the nationwide access of
patients.
Research and education
Several issues appear to have been overlooked in developing
countries. Data regarding the exact burden of malignancies
are lacking, and most of the preventive, diagnostic, and ther-
apeutic policies are based on the data and studies performed
in high-income countries. The increasing incidence of malig-
nancies in developing countries and the different characteris-
tics among populations underscore the need for high-quality
data collection and implementation of registries in these
countries. Tangka et al. reported a wide variation in data reg-
istration in different countries, ranging from nearly 100% in
North American countries to less than 10% in Asia and Cen-
tral and South Americas, and only 2% in Africa.38 These are
only but a few examples of the existing ignorance vis-à-vis
cancer that should be addressed by a target-oriented and
continuous research programme. One of the principal pur-
poses of a COU in a developing country should be promoting
research in order to produce agents of new drug classes that
have not yet been introduced to their market but have been
successful in other regions. Furthermore, trials should be de-
signed in order to evaluate the cardiovascular effects of de-
veloped cancer treatment agents in these countries.
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It has been postulated that individual responses based on
genetic and environmental variations are responsible for pro-
voking myocardial dysfunction or causing cardio-protective
effects among patients receiving cancer therapy. Different
genetic SNP types have been recognized as being involved
in the carrying, metabolism, and cytotoxic features of anti-
cancer drugs and therapies.39–41 There is a dearth of data in
the existing literature on this subject; nevertheless, further
evaluations and recognition of the diverse patterns in multi-
ethnicity trials are required so as to address cardio-oncology
concerns in different regions.
A large and dedicated team boasting expertise ranging
from basic science to different medical disciplines is needed
to tackle the challenges mentioned throughout this article.
With respect to education, the shortage of specialists and
healthcare personnel in the cardio-oncology field, given that
it is a nascent scientific endeavour, is far more noticeable in
developing countries than in the developed world. We have
recently launched an educational programme to train special-
ists with the ultimate goal of establishing a number of
cardio-oncology centres nationwide. Undoubtedly, we are
acutely aware of the daunting challenges ahead, financially
and chronologically, in providing the required infrastructure
and training sufficient trained personnel.
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